[go: up one dir, main page]

MA41140A - Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg - Google Patents

Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg

Info

Publication number
MA41140A
MA41140A MA041140A MA41140A MA41140A MA 41140 A MA41140 A MA 41140A MA 041140 A MA041140 A MA 041140A MA 41140 A MA41140 A MA 41140A MA 41140 A MA41140 A MA 41140A
Authority
MA
Morocco
Prior art keywords
quinazoline
dioxo
sulfonamide derivatives
parg inhibitors
parg
Prior art date
Application number
MA041140A
Other languages
English (en)
Inventor
Niall M Hamilton
James R Hitchin
Colin Hutton
Allan Jordan
Alison E Mcgonagle
Kate Mary Smith
Ian Waddell
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MA41140A publication Critical patent/MA41140A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MA041140A 2014-12-12 2015-12-10 Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg MA41140A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422098 2014-12-12

Publications (1)

Publication Number Publication Date
MA41140A true MA41140A (fr) 2017-10-17

Family

ID=54937266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041140A MA41140A (fr) 2014-12-12 2015-12-10 Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg

Country Status (15)

Country Link
US (1) US10239843B2 (fr)
EP (1) EP3230273A1 (fr)
JP (1) JP2017537137A (fr)
KR (1) KR20170093967A (fr)
CN (1) CN107207467A (fr)
AU (1) AU2015359082A1 (fr)
BR (1) BR112017012402A2 (fr)
CA (1) CA2969296A1 (fr)
IL (1) IL252575A0 (fr)
MA (1) MA41140A (fr)
MX (1) MX2017007478A (fr)
RU (1) RU2017124425A (fr)
SG (1) SG11201704686UA (fr)
WO (1) WO2016092326A1 (fr)
ZA (1) ZA201704382B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
UY36636A (es) 2015-04-21 2016-11-30 Glaxosmithkline Ip Dev Ltd Compuesto derivado de butanamida con actividad antiparasitaria
WO2021055744A1 (fr) * 2019-09-20 2021-03-25 Ideaya Biosciences, Inc. Dérivés de sulfonamido d'indole et d'indazole substitués en position 4 en tant qu'inhibiteurs de parg
CN116583286A (zh) * 2020-12-24 2023-08-11 某久拉斯株式会社 四氢噻吩并嘧啶磺酰胺化合物
WO2023057389A1 (fr) 2021-10-04 2023-04-13 Forx Therapeutics Ag Composés inhibiteurs de parg
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
AR128499A1 (es) 2022-02-14 2024-05-15 Arase Therapeutics Inc Inhibidores de parg
CN116693519A (zh) 2022-03-04 2023-09-05 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2023175184A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer
WO2023175185A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
KR20240165402A (ko) 2022-03-23 2024-11-22 아이디어야 바이오사이언시스 인코포레이티드 Parg의 억제제로서의 피페라진 치환된 인다졸 화합물
IL316261A (en) * 2022-04-28 2024-12-01 Danatlas Pharmaceuticals Co Ltd Tricyclic and heterocyclic derivatives, preparations and uses thereof
KR20250012101A (ko) 2022-05-17 2025-01-23 858 테라퓨틱스, 인크. Parg의 억제제
AR129339A1 (es) * 2022-05-17 2024-08-14 858 Therapeutics Inc Inhibidores de parg
EP4559912A1 (fr) * 2022-07-19 2025-05-28 Evopoint Biosciences Co., Ltd. Composé cyclique hétéroaromatique contenant du soufre, composition pharmaceutique de celui-ci et son utilisation
EP4311829A1 (fr) 2022-07-28 2024-01-31 Nodus Oncology Limited Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer
WO2024074497A1 (fr) 2022-10-03 2024-04-11 Forx Therapeutics Ag Composé inhibiteur de parg
WO2024173524A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés benzimidazoles à substitution hétéroaryle
WO2024173530A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés pyrazolo/imidazo pyridine à substitution hétéroaryle
WO2024173453A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution hétéroaryle
WO2024173514A1 (fr) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution amide et ester
WO2024209035A1 (fr) 2023-04-05 2024-10-10 Forx Therapeutics Ag Composés inhibiteurs de parg
CN119143747A (zh) * 2023-06-16 2024-12-17 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
WO2025046148A1 (fr) 2023-09-01 2025-03-06 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
WO2025056017A1 (fr) * 2023-09-14 2025-03-20 Zai Lab (Shanghai) Co., Ltd. Hétéroaryles bicycliques fusionnés utilisés en tant qu'inhibiteurs de parg et leurs utilisations
WO2025073870A1 (fr) 2023-10-03 2025-04-10 Forx Therapeutics Ag Composé inhibiteur de parg
WO2025093755A1 (fr) 2023-11-01 2025-05-08 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
WO2025111339A1 (fr) * 2023-11-21 2025-05-30 858 Therapeutics, Inc. Traitement du cancer avec un inhibiteur de parg
WO2025133396A1 (fr) 2023-12-22 2025-06-26 Forx Therapeutics Ag Nouveaux inhibiteurs de parg bicyclo hétéroaryles
WO2025165942A1 (fr) * 2024-01-31 2025-08-07 Synnovation Therapeutics, Inc. Composés tricycliques utilisés en tant qu'inhibiteurs de parg
WO2025245087A1 (fr) * 2024-05-23 2025-11-27 Synnovation Therapeutics, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de parg

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (fr) * 1979-12-03 1983-11-29 Ikuo Ueda Derives de quinazoline
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) * 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070032496A1 (en) * 2005-07-26 2007-02-08 Hergenrother Paul J Compounds for the Treatment of Neurodegeneration and Stroke
EP1979314B1 (fr) 2006-01-24 2013-01-09 Eli Lilly & Company Sulfamide d'indole modulateur de récepteurs de la progestérone
CA2645583A1 (fr) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Procedes d'inhibition des proteines kinase btk et syk
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
RU2011105810A (ru) 2008-07-17 2012-08-27 Асахи Касеи Фарма Корпорейшн (Jp) Азотсодержащие бициклические гетероциклические соединения
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
WO2011140325A1 (fr) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
PH12013501489A1 (en) 2010-12-17 2013-08-28 Hoffmann La Roche Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP2471363A1 (fr) * 2010-12-30 2012-07-04 Bayer CropScience AG Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes
WO2013027168A1 (fr) * 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
WO2013067300A1 (fr) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
JP2014106019A (ja) 2012-11-26 2014-06-09 Stack Electronics Co Ltd プローブ
US9938236B2 (en) 2012-12-27 2018-04-10 Drexel University Antiviral agents against HBV infection
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg

Also Published As

Publication number Publication date
US20180016242A1 (en) 2018-01-18
ZA201704382B (en) 2019-09-25
IL252575A0 (en) 2017-07-31
EP3230273A1 (fr) 2017-10-18
BR112017012402A2 (pt) 2017-12-26
CA2969296A1 (fr) 2016-06-16
SG11201704686UA (en) 2017-07-28
AU2015359082A1 (en) 2017-06-29
RU2017124425A (ru) 2019-01-14
MX2017007478A (es) 2018-05-04
WO2016092326A1 (fr) 2016-06-16
CN107207467A (zh) 2017-09-26
US10239843B2 (en) 2019-03-26
JP2017537137A (ja) 2017-12-14
KR20170093967A (ko) 2017-08-16

Similar Documents

Publication Publication Date Title
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
HUE058009T2 (hu) 1,3-Tiazol-2-il szubsztituált benzamid-származékok
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
DK3319956T3 (da) Substituerede oxopyridinderivater
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
DK3094631T4 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
HUE040304T2 (hu) 2-Amino-6-(difluor-metil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridinek, mint bace1 inhibitorok
EP3457851A4 (fr) Dérivés de sobétirome
EP3283171A4 (fr) Dérivés d'amphotéricine b
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
LT3273947T (lt) Kompozicija, skirta akių sveikatai
EP2953470A4 (fr) Purines 2,6,7 substituées utilisées en tant qu'inhibiteurs de hdm2
SMT202200179T1 (it) Composizione acquosa oftalmica.
EP3102571A4 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
IL260011A (en) History of 5,3-diphenyl-diazole water-soluble compounds
LT3341380T (lt) Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui